Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Hormone Therapy
- Colorectal Cancer
- Hematology
- Pancreatic Cancer
- Chemotherapy and Radiotherapy
- Sarcomas
- Thoracic Oncology
- Urological Cancers
Abstract
Citation: Clin Oncol. 2020;5(1):1691.DOI: 10.25107/2474-1663-v5-id1691
Sarcoid-like Reaction Detected by 18F-FDG PET/CT in a Patient with Gastrointestinal Stromal Tumor (GIST) PostTherapy with Multi-Targeted Receptor Tyrosine Kinase (RTK) Inhibitor Sunitinib
Mahmoud Aly, Chaitanya Rojulpote, Esha Kothekar1, Therese Seierstad and Mona-Elisabeth Revheim
Department of Radiology, Hospital of the University of Pennsylvania, USA Division of Radiology and Nuclear Medicine, Oslo University Hospital, Norway Institute of Clinical Medicine, University of Oslo, Norway
*Correspondance to: Mona-Elisabeth Revheim
PDF Full Text Case Report | Open Access
Abstract:
A 52 years old male patient, with a history of Gastrointestinal Stromal Tumor (GIST) in the small intestines with metastasis to the liver and peritoneum, with pathology showing mutation type Exon11. The patient underwent 18F-FDG PET/CT scan that showed lesions with moderate FDG uptake. The patient was given Sunitinib 50 mg p.os and a 18F-FDG PET/CT scan performed two weeks later showed marked reduced FDG uptake in all lesions. However, due to side effects, Sunitinib was first discontinued and then restarted after three weeks with 25 mg (half dose). A follow-up 18F-FDG PET/ CT scan three months later showed stable disease but high FDG uptake in multiple cervical, axillary and mediastinal lymph nodes.
Keywords:
Sarcoid; FDG PET/CT; GIST; RTK; Sunitinib
Cite the Article:
Aly M, Rojulpote C, Kothekar E, Seierstad T, Revheim M-E. Sarcoid-like Reaction Detected by 18F-FDG PET/ CT in a Patient with Gastrointestinal Stromal Tumor (GIST) Post-Therapy with Multi-Targeted Receptor Tyrosine Kinase (RTK) Inhibitor Sunitinib. Clin Oncol. 2020; 5: 1691.